|Table of Contents|

Correlation between tumor microenvironment and efficacy and prognosis of neoadjuvant chemoradiotherapy for rectal cancer:A Hyperion imaging system analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1452-1457
Research Field:
Publishing date:

Info

Title:
Correlation between tumor microenvironment and efficacy and prognosis of neoadjuvant chemoradiotherapy for rectal cancer:A Hyperion imaging system analysis
Author(s):
CHEN Hong1; ZHANG Jihong2; ZHAO Jianguo2; WU Xinlin3; HAO Qin3; GUO Jiaxing2; XING Guosheng3; AN Zhiling2; BAO Yingna2
1.Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Hohhot 010050,China;2.Department of Radiotherapy;3.Department of Gastrointestinal Surgery,Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Hohhot 010050,China.
Keywords:
locally advanced rectal cancer; neoadjuvant chemoradiotherapy; tumor microenvironment; effect; prognosis
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2024.08.014
Abstract:
Objective:To explore the correlation between tumor microenvironment characteristics and the efficacy and prognosis of neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal cancer (LARC) patients.Methods:Four LARC patients who received NCRT in our hospital from October 2020 to April 2021 were retrospectively analyzed.26 metal-labeled antibodies were used to label paraffin sections of patients,and the labeled samples were then detected and analyzed with the Hyperion imaging system and the clinical efficacy and prognosis were analyzed.Results:There were significant differences in the degree of remission and prognosis after NCRT in four LARC patients.Three different tumor microenvironment characteristics were observed in Hyperion system,including immune cell enriched type,immune cell deficient type and immunosuppressive cell dominant type.CD8+T cells,Foxp3+ regulatory T cells,CD56+ natural killer cells,CD14+ monocytes,CD11b+ macrophages,CD11c+ dendritic cells and Ki-67 were significantly expressed in their respective samples (P＜0.05).PD-1 and PD-L1 were only highly expressed in patient two.Conclusion:LARC patients have significant tumor microenvironment heterogeneity,and its heterogeneity can lead to differences in the efficacy and prognosis of patients after NCRT.

References:

［1］ ORONSKY B,REID T,LARSON C,et al.Locally advanced rectal cancer:The past,present,and future［J］.Semin Oncol,2020,47(1):85-92.
［2］ MAAS M,NELEMANS PJ,VALENTONI V,et al.Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data［J］.Lancet Oncol,2010,11(9):835-844.
［3］ 张馨元,付永峰,白立立,等.K-Ras、BRAF、PIK3CA基因突变与直肠癌新辅助放化疗疗效及预后的关系［J］.现代肿瘤医学,2023,31(16):3051-3055. ZHANG XY,FU YF,BAI LL,et al.Relationship between K-Ras,BRAF,PIK3CA gene mutation and the efficacy and prognosis of neoadjuvant chemoradiotherapy for rectal cancer［J］.Modern Oncology,2023,31(16):3051-3055.
［4］ HU H,CHEN Y,TAN S,et al.The research progress of antiangiogenic therapy,immune therapy and tumor microenvironment［J］.Front Immunol,2022,13:802846.
［5］ EL SC,KIRILOVSKY A,VANDEM,et al.A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy［J］.Clin Cancer Res,2020,26(19):5198-5207.
［6］ LIU X,ZHENG S,PENG Y,et al.Construction of the prediction model for locally advanced rectal cancer following neoadjuvant chemoradiotherapy based on pretreatment tumor-Infiltrating macrophage-associated biomarkers［J］.Onco Targets Ther,2021,14:2599-2610.
［7］ XIE S,ZHANG XY,SHAN XF,et al.Hyperion image analysis depicts a preliminary landscape of tumor immune microenvironment in OSCC with lymph node metastasis［J］.J Immunol Res,2021,2021:9975423.
［8］ ORHAN A,KHESRAWI F,TVILLIN MM,et al.Tumor-infiltrating lymphocytes as biomarkers of treatment response and long-term survival in patients with rectal cancer:asystematic review and meta-analysis［J］.Cancers (Basel),2022,14(3):636.
［9］ JI D,SONG C,LI Y,et al.Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect andinhibits metastasis in rectal cancer［J］.J Immunother Cancer,2020,8(2):e000826.
［10］ SHINTO E,HASE K,HASHIGUCHI Y,et al.CD8+ and Foxp3+ tumor-infiltrating T cells before and after chemoradiotherapy forrectal cancer［J］.Ann Surg Oncol,2014,21(Suppl 3):S414-S421.
［11］ DONADON M,HUDSPETH K,CIMINO M,et al.Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival［J］.J Gastrointest Surg,2017,21(8):1226-1236.
［12］ TOPALIAN SL,HODI FS,BRAHMER JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med,2012,366(26):2443-2454.
［13］ 李一鑫,路丹.PD-1/PD-L1抑制剂治疗晚期卵巢癌的研究进展［J］.现代肿瘤医学，2021,29(15):2741-2744. LI Yixin,LU Dan.Research progress of PD-1/PD-L1 inhibitor in the treatment of advanced ovarian cancer［J］.Modern Oncology,2021,29(15):2741-2744.
［14］ 廖元宇,白玉贤.PD-1/PD-L1抑制剂治疗晚期肝细胞癌的机制及研究进展［J］.现代肿瘤医学，2021,29(11):1989-1993. LIAO Yuanyu,BAI Yuxian.The mechanism and research progress of PD-1/PD-L1 inhibitor in the treatment of advanced hepatocellular carcinoma［J］.Modern Oncology,2021,29(11):1989-1993.
［15］ ANDRE T,SHIU KK,KIM TW,et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer［J］.N Engl J Med,2020,383(23):2207-2218.
［16］ GANESH K,STADLER ZK,CERCEK A,et al.Immunotherapy in colorectal cancer:rationale,challenges and potential［J］.Nat Rev Gastroenterol Hepatol,2019,16(6):361-375.
［17］ TENG MW,NGIOW SF,RIBAS A,et al.Classifying cancers based on T-cell infiltration and PD-L1［J］.Cancer Res,2015,75(11):2139-2145.
［18］ CHALABI M,FANCHI LF,DIJKSTRA KK,et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers［J］.Nat Med,2020,26(4):566-576.
［19］ DALLE FC,MEZZALIRA S,POLESEL J,et al.A panel of tumor biomarkers to predict complete pathological response to neoadjuvant treatment in locally advanced rectal cancer［J］.Oncol Res,2022,28(9):847-855.
［20］ 阿布都维力·阿布都热合曼,阿洪江·买尔甫,高维鸽.直肠癌组织中COX-2、TCF-4、Ki-67表达水平与其根治术后复发转移的关系分析［J］.中华保健医学杂志,2023,25(2):215-217. ABUDUREHEMAN ABDWL,MAIERFU AHJ,GAO WG.Analysis of the relationship between COX-2,TCF-4 and Ki-67 expression levels in rectal cancer tissues and recurrence and metastasis after radical surgery［J］.Chin J Health Care Med,2023,25(2):215-217.
［21］ WANG H,TIAN T,ZHANG J.Tumor-associated macrophages (TAMs) in colorectal cancer (CRC):from mechanism to therapy and prognosis［J］.Int J Mol Sci,2021,22(16):8470.
［22］ WU Z,ZHANG Z,LEI Z,et al.CD14:Biology and role in the pathogenesis of disease［J］.Cytokine Growth Factor Rev,2019,48:24-31.
［23］ HSU YL,CHEN YJ,CHANG WA,et al.Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1［J］.Int J Mol Sci,2018,19(8):2427.
［24］ CHANDRA R,KARALIS JD,LIU C,et al.The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis［J］.Cancers (Basel),2021,13(24):6206.
［25］ WANG WW,YUAN XL,CHEN H,et al.CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer［J］.Oncotarget,2015,6(32):33486-33499.

Memo

Memo:
内蒙古科技计划项目（编号：2019GG150）；内蒙古自然科学基金项目（编号：2019MS08124）
Last Update: 1900-01-01